DPx Launches as Global Provider of Pharmaceutical Services, Fine Chemicals and Proprietary Technologies
DPx Holdings BV (DPx), privately owned by JLL Partners and Royal DSM, yesterday (11 March) launched as a leading global contract development and manufacturing organization (CDMO) for the pharmaceutical and related industries. DPx is the result of a USD $2.65 billion transaction between JLL Partners, a leading middle-market private equity firm, and Royal DSM, the global Life Sciences and Materials Sciences company. DPx is 51% owned by JLL Partners and 49% by Royal DSM. With headquarters in Durham, N.C., DPx’s global footprint includes 24 locations across North America, Europe, Latin America and Australia with more than 8000 employees.
Formerly known by its provisional name “NewCo,” DPx is the corporate parent of a group of business units that is comprised of three distinct brands focused on pharmaceutical services, fine chemicals and products and proprietary technologies.These units are the result of combining DSM Pharmaceutical Products (DPP), Patheon and Banner Life Sciences. The company’s business unit structure is as follows:
• Pharmaceutical services will operate under the Patheon brand name and include the commercial manufacturing (CMO) capabilities, pharmaceutical product development services (PDS) as well as Biosolutions and Biologics (Bio) businesses of DPP.
• Fine chemicals, or the ES/IM and active pharmaceutical ingredients (API) businesses, which will operate under the brand name DSM Fine Chemicals.
• Proprietary products and technologies, which will operate under the Banner Life Sciences brand name.
Patheon is the industry’s end-to-end supplier providing an integrated supply chain model to customers. Patheon delivers a full spectrum of pharmaceutical development and manufacturing services ranging from APIs, Biologics and Biosolutions, as well as pharmaceutical product development services (PDS) and commercial manufacturing (CMO) capabilities. In addition, DSM Fine Chemicals will handle complicated APIs and finished dosage forms for customers, and Banner Life Sciences will offer its own proprietary and nutraceutical products to the market.
“This is an exciting day for our customers and employees. We believe that combining the capabilities and experience of both Patheon and DPP immediately positions us as the pharmaceutical industry’s partner of choice,” said Jim Mullen, CEO of DPx. “Today we are better positioned to add scale, new value chain capabilities and technologies, as well as expand our end-to-end service offerings to our customers as a global, comprehensive solution provider to the industry.”
DPx’s 2014 sales are anticipated to be about USD $2 billion (pro-forma). The structure is organized around the customer’s needs and operational efficiency.
“We are thrilled to announce the close of this landmark deal,” said Paul S. Levy, Managing Director of JLL Partners. “It is the result of much hard work and strategic foresight and is a demonstration of how we increase value through investment in growth and market positioning.”
“We are eager to build on the strong reputation each of our businesses has with existing customers,” said Stefan Doboczky, DPx board member and member of the DSM Managing Board. “We understand companies are seeking collaborative relationships with their suppliers, and we are truly committed to helping them navigate the challenges posed by the ever-changing nature of the healthcare marketplace.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance